Work

New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond

Year: 2008
Type: review
Abstract: This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs.
Source: Circulation
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2114076019
FWCI: 2.519
Cites: 90
Cited by: 208
Related to: 10